Loading cancer entity…
Loading cancer entity…
Clinical trials
9 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02682693 | Denosumab as an add-on Neoadjuvant Treatment (GeparX)(GeparX) | completed | Phase 2 | 780 | GBG Forschungs GmbHOTHER | 1 | Feb 2, 2021 | clinicaltrials |
| NCT01583426 | Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto)(GeparSepto) | completed | Phase 3 | 1,229 | GBG Forschungs GmbHOTHER | 1 | Aug 6, 2020 |
| clinicaltrials |
| NCT02125344 | A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) | completed | Phase 3 | 961 | GBG Forschungs GmbHOTHER | 1 | Jul 13, 2017 | clinicaltrials |
| NCT02199418 | Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer(SHPD001) | completed | Phase 2 | 132 | RenJi HospitalOTHER | 1 | Jan 25, 2017 | clinicaltrials |
| NCT01426880 | Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer(GeparSixto) | completed | Phase 2 / Phase 3 | 595 | GBG Forschungs GmbHOTHER | 1 | Feb 15, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Feb 2, 2021source: clinicaltrials